James F III Oliviero
CIK 1434718 · CEO, President and Director · last filed 2025-06-12
James F III Oliviero is a CEO, President and Director who has filed 66 SEC Form 4 insider transactions across 3 companies since 2008. The most recent filing, for NVCT, was dated Jun 12, 2025. Across all open-market trades the lifetime net is −$15.0M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $940.6K across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$940.6K
3
66
-$15.03M
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| NVCT | Director | 87,828 | $10.71 | $940.6K | $0 | 4 | 2025-06-12 |
| Checkpoint Therapeutics, Inc. (CKPT) Delisted | CEO, President and Director | 0 | $4.26 | $0 | -$4.34M | 22 | 2025-05-30 |
| KERYX BIOPHARMACEUTICALS INC (KERX) Delisted | Chief Financial Officer | 209,406 | — | — | -$10.69M | 39 | 2015-07-08 |
Recent Filings
66 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2025-06-12 | NVCT | Grant (A) | +30,000 | $0 | EDGAR |
| 2025-05-30 | Checkpoint Therapeutics, Inc. (CKPT) Delisted | U | −3,759,929 | $0 | EDGAR |
| 2025-04-03 | Checkpoint Therapeutics, Inc. (CKPT) Delisted | Sell (S) | −15,090 | -$61.0K | EDGAR |
| 2025-02-11 | Checkpoint Therapeutics, Inc. (CKPT) Delisted | Sell (S) | −19,564 | -$64.0K | EDGAR |
| 2025-01-31 | Checkpoint Therapeutics, Inc. (CKPT) Delisted | Grant (A) | +1,500,000 | $0 | EDGAR |
| 2024-12-20 | Checkpoint Therapeutics, Inc. (CKPT) Delisted | Mixed | −1,722,397 | -$3.07M | EDGAR |
| 2024-12-17 | Checkpoint Therapeutics, Inc. (CKPT) Delisted | Grant (A) | +2,077,700 | $0 | EDGAR |
| 2024-06-28 | Checkpoint Therapeutics, Inc. (CKPT) Delisted | Mixed | −62,500 | -$50.5K | EDGAR |
| 2024-06-13 | NVCT | Grant (A) | +30,000 | $0 | EDGAR |
| 2024-05-24 | Checkpoint Therapeutics, Inc. (CKPT) Delisted | Grant (A) | +1,660,000 | $0 | EDGAR |